Out of date information, search another

Lisinopril/Hydrochlorothiazide 20 Mg/12.5 Mg Tablets

Out of date information, search another

Informations for option: Lisinopril/Hydrochlorothiazide 20 Mg/12.5 Mg Tablets, show other option

Document: document 0 change

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Lisinopril/Hydrochlorothiazide 20 mg/12.5 mg Tablet

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 20 mg of lisinopril (as dihydrate) and 12.5 mg of hydrochlorothiazide.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Tablet

Lisinopril/Hydrochlorothiazide 20 mg/12.5 mg Tablet: A white, 10.5 mm, round, biconvex, bevelled edge tablet debossed with LH2 over M on one side of the tablet and a score line on the other side.

The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Treatment of essential hypertension.

Lisinopril/Hydrochlorothiazide Tablet fixed dose combination is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled on lisinopril alone (or hydrochlorothiazide alone).

4.2 Posology and method of administration

Essential Hypertension

The selection of a suitable antihypertensive dose of lisinopril and hydrochlorothiazide will depend upon the clinical evaluation of the patient.

Lisinopril and Hydrochlorothiazide should be taken once daily. As with other medicines that are taken once daily, Lisinopril/Hydrochlorothiazide should be taken at about the same time each day.

The administration of the fixed combination lisinopril and hydrochlorothiazide is usually recommended after dosage titration with the individual components.

When clinically appropriate a direct change from monotherapy to fixed combination may be considered.

20 mg/12.5 mg tablets may be administrated in patients whose blood pressure is not adequately controlled by 20 mg lisinopril alone.

A maximum daily dose of 40 mg lisinopril/ 25 mg hydrochlorothiazide should not be exceeded.

Renal Insufficiency

Thiazides may not be appropriate diuretics for use in patients with renal impairment and are ineffective at creatinine clearance values of 30 ml/min or below (i.e. moderate or severe renal insufficiency).

Lisinopril and hydrochlorothiazide combination is not to be used as initial therapy in any patient with renal insufficiency.

In patients with creatinine clearance of>30 and <80 ml/min, lisinopril and hydrochlorothiazide combination may be used, but only after titration of the individual components. The recommended dose of lisinopril, when used alone, in mild renal insufficiency, is 5 to 10 mg.

Prior Diuretic Therapy

Symptomatic hypotension may occur following the initial dose of lisinopril and hydrochlorothiazide combination; this is more likely in patients who are volume and/or salt depleted as a result of prior diuretic therapy. The diuretic therapy should be discontinued for 2-3 days prior to initiation of therapy with lisinopril and hydrochlorothiazide combination. If this is not possible, treatment should be started with lisinopril alone, in a 5 mg dose.

Elderly

No adjustment of dosage is required in the elderly.

In clinical studies the efficacy and tolerability of lisinopril and hydrochlorothiazide, administered concomitantly, were similar in both elderly and younger hypertensive patients.

Lisinopril, within a daily dosage range of 20 to 80 mg, was equally effective in the elderly (65 years or over) and non-elderly hypersensitive patients, monotherapy with lisinopril was as effective in reducing diastolic blood pressure as monotherapy with either hydrochlorothiazide or atenolol. In clinical studies, age did not affect the tolerability of lisinopril.

Paediatric Use

Safety and effectiveness in children have not been established.

4.3 Contraindications

- Hypersensitivity to lisinopril, to any of the excipients listed in section 6.1 or any other angiotensin converting enzyme (ACE) inhibitor.

- Hypersensitivity to hydrochlorothiazide or other sulphonamide-derived drugs.

- History of angioedema with previous ACE inhibitor therapy.

- Hereditary or idiopathic angioedema.

- Second and third trimesters of pregnancy (see sections 4.4 and 4.6).

- Severe renal impairment (creatinine clearance < 30 ml/min).

- Anuria.

- Severe hepatic impairment.

4.4 Special warnings and precautions for use

Lithium

Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. Diuretic agents and ACE inhibitors reduce the renal clearance of lithium and pose a high risk of lithium toxicity. The combination of lisinopril and hydrochlorothiazide with lithium is therefore not recommended and careful monitoring of serum lithium levels should be performed if the combination proves necessary (see section 4.4).

Potassium supplements, potassium-sparing diuretics or potassium-containing salt substitutes.

The potassium losing effect of thiazide diuretics is usually attenuated by the potassium conserving effect of lisinopril. The use of potassium supplements, potassium-sparing agents or potassium-containing salt substitutes, particularly in patients with impaired renal function or diabetes mellitus, may lead to a significant increase in serum potassium. If concomitant use of lisinopril/hydrochlorothiazide and any of these agents is required, they should be used with caution and with frequent monitoring of serum potassium (see section 4.4).

Torsades de pointes-inducing medicinal products Because of the risk of hypokalaemia the concomitant administration of hydrochlorothiazide and medicinal products that induce torsades de pointes, e.g. some antiarrhythmics, some anti-psychotics and other drugs known to induce torsades de pointes, should be used with caution.

Tricyclic antidepressants/ antipsychotics /anaesthetics

Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and antipsychotics with ACE inhibitors may result in further lowering of blood pressure (see section 4.4).

Non-steroidal anti-inflammatory/anti-rheumatic drugs (NSAID)

Chronic administration of NSAID (selective COX-2 inhibitors, acetylsalicylic acid >3 g/day and non-selective NSAIDs) may reduce the antihypertensive and diuretic effect of ACE inhibitors and thiazide diuretics. NSAID and ACE inhibitors exert an additive effect on the increase in serum potassium and may result in a deterioration of renal function. This effect is normally reversible. Rarely, acute renal failure may occur, especially in patients with compromised renal function such as the elderly and dehydrated.

Gold

Nitritoid reactions (symptoms of vasodilatation including flushing, nausea, dizziness and hypotension, which can be very severe) following injectable gold (for example, sodium aurothiomalate) have been reported more frequently in patients receiving ACE inhibitor therapy.

Sympathomimetics

Sympathomimetics can reduce the antihypertensive effect of ACE inhibitors.

Other antihypertensives

Concomitant use of these agents may increase the hypotensive effect of lisinopril/hydrochlorothiazide. Concomitant use of glyceryl trinitrate and other nitrates or other vasodilators may further reduce the blood pressure.

Antidiabetics

Epidemiological studies indicate that concomitant administration of ACE inhibitors and antidiabetic medicinal products (insulins, oral hypoglycaemic agents) may cause an increased blood glucose lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely to occur during the first weeks of combination treatment and in patients with renal impairment.

Amphotericin B (parenteral), carbenoxolone, corticosteroids, corticotropin (ACTH) or stimulant laxatives

Hydrochlorothiazide may intensify electrolyte imbalance, particularly hypokalaemia.

Calcium salts

Increased serum calcium levels due to decreased excretion may occur when administered concurrently with thiazide diuretics.

Cardiac glycosides

There is increased risk of digitalis toxicity associated with thiazide induced hypokalaemia.

Colestyramine and colestipol

These may delay or reduce absorption of hydrochlorothiazide. Therefore sulphonamide diuretics should be taken at least 1 hour before or 4-6 hours after intake of these agents.

Non-depolarizing muscle relaxants (e.g. tubocurarine chloride)

The effect of these agents may be potentiated by hydrochlorothiazide.

Trimethoprim

Concomitant administration of ACE inhibitors and thiazides with trimethoprim increases the risk of hyperkalaemia.

Sotalol

Thiazide induced hypokalaemia can increase the risk of sotalol induced arrhythmia.

Allopurinol

Concomitant administration of ACE inhibitors and allopurinol increases the risk of renal damage and can lead to an increased risk of leucopoenia.

Ciclosporin

Concomitant administration of ACE inhibitors and ciclosporin increases the risk of renal damage and hyperkalaemia.

Lovastatin

Concomitant administration of ACE inhibitors and lovastatin increases the risk of hyperkalaemia.

Cytostatics, immunosuppressives, procainamide

Concomitant administration of ACE inhibitors can lead to increased risk of leucopenia (see section 4.4).

Alcohol

5 When used with alcohol, lisinopril/hydrochlorothiazide combination products may have a mild to moderate effect on the ability to drive and use machines (see section 4.7).

4.5 Interaction with other medicinal products and other forms of interaction

Lithium

Potassium supplements, potassium-sparing diuretics or potassium-containing salt substitutes.

Tricyclic antidepressants/ antipsychotics /anaesthetics Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and antipsychotics with ACE inhibitors may result in further lowering of blood pressure (see section 4.4).

Non-steroidal anti-inflammatory/anti-rheumatic drugs (NSAID)

Gold

Sympathomimetics

Sympathomimetics can reduce the antihypertensive effect of ACE inhibitors. Other antihypertensives

Antidiabetics

Amphotericin B (parenteral), carbenoxolone, corticosteroids, corticotropin (ACTH) or stimulant laxatives

Hydrochlorothiazide may intensify electrolyte imbalance, particularly hypokalaemia.

Calcium salts

Increased serum calcium levels due to decreased excretion may occur when administered concurrently with thiazide diuretics.

Cardiac glycosides

There is increased risk of digitalis toxicity associated with thiazide induced hypokalaemia.

Colestyramine and colestipol

These may delay or reduce absorption of hydrochlorothiazide. Therefore sulphonamide diuretics should be taken at least 1 hour before or 4-6 hours after intake of these agents.

Non-depolarizing muscle relaxants (e.g. tubocurarine chloride)

The effect of these agents may be potentiated by hydrochlorothiazide.

Trimethoprim

Concomitant administration of ACE inhibitors and thiazides with trimethoprim increases the risk of hyperkalaemia.

Sotalol

Thiazide induced hypokalaemia can increase the risk of sotalol induced arrhythmia.

Allopurinol

Concomitant administration of ACE inhibitors and allopurinol increases the risk of renal damage and can lead to an increased risk of leucopoenia.

Ciclosporin

Concomitant administration of ACE inhibitors and ciclosporin increases the risk of renal damage and hyperkalaemia.

Lovastatin

Concomitant administration of ACE inhibitors and lovastatin increases the risk of hyperkalaemia.

Cytostatics, immunosuppressives, procainamide

Concomitant administration of ACE inhibitors can lead to increased risk of leucopenia (see section 4.4).

Alcohol

6 When used with alcohol, lisinopril/hydrochlorothiazide combination products may have a mild to moderate effect on the ability to drive and use machines (see section 4.7).

4.6 Fertility, Pregnancy and lactation

Pregnancy

The use of ACE inhibitors is not recommended during the first trimester of pregnancy (see section 4.4). The use of ACE inhibitors is contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).

Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Unless continued ACE inhibitors therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.

ACE inhibitor therapy exposure during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See also section 5.3 'Preclinical safety data'). Should exposure to ACE inhibitors have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see also sections 4.3 and 4.4).

Hydrochlorothiazide:

There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the second and third trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.

Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease.

Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare situations where no other treatment could be used.

Lactation

ACE-inhibitors:

Because no information is available regarding the use of lisinopril/hydrochlorothiazide during breast-feeding,

lisinopril/hydrochlorothiazide is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.

Hydrochlorthiazide:

7 Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit the milk production. The use of Lisinopril/Hydrochlorothiazide during breast feeding is not recommended. If Lisinopril/Hydrochlorothiazide is used during breast feeding, doses should be kept as low as possible.

4.7 Effects on ability to drive and use machines

As with other antihypertensives, lisinopril/hydrochlorothiazide combination products may have a mild to moderate effect on the ability to drive and use machines. Especially at the start of the treatment or when the dose is modified, and also when used in combination with alcohol, but these effects depend on the individual's susceptibility.

4.8 Undesirable effects

The following undesirable effects have been observed and reported during treatment with Lisinopril/Hydrochlorothiazide with the following frequencies: Very common (>10%), common (>1%,<10%), uncommon (>0.1%, <1%), rare (>0.01%, <0.1%), very rare (<0.01%), not known (cannot be estimated from the available data).

The most commonly reported ADRs are cough, dizziness, hypotension, and headache which may occur in 1 to 10% of treated patients. In clinical studies, side effects have usually been mild and transient, and in most instances have not required interruption of therapy.

Lisinopril:

Blood and the lymphatic system disorders:

Rare

Decreases in haemoglobin, decreases in haematocrit.

Very rare

Bone marrow depression, anaemia, thrombocytopenia,

leucopenia, neutropenia, agranulocytosis (see section 4.4), haemolytic anaemia,

	lymphadenopathy, autoimmune disease.
Endocrine disorders
Rare	Inappropriate antidiuretic hormone secretion
Metabolism and nutrition disorders:
Very rare	Hypoglycaemia.
Psychiatric disorders
Uncommon	Mood alterations, depressive symptoms.
Rare	Mental confusion.
Nervous system disorders
Common	Dizziness, headache, syncope.
Uncommon	Paraesthesia, vertigo, taste disturbance, sleep disturbances.
Rare	Olfactory disturbance.
Cardiac disorders
Uncommon	Myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients (see section 4.4), palpitations, tachycardia.
Vascular disorders
Common	Orthostatic effects (including orthostatic hypotension).
Uncommon	Raynaud's syndrome.
Respiratory, thoracic and mediastinal disorders
Common	Cough (see section 4.4).
Uncommon	Rhinitis.
Very rare	Bronchospasm, sinusitis, allergic alveolitis/eosinophilic pneumonia.
Gastrointestinal disorders
Common	Diarrhoea, vomiting.
Uncommon	Nausea, abdominal pain and indigestion.
Rare	Dry mouth.
Very rare	Pancreatitis, instestinal angioedema.

Hepato-biliary disorders
Uncommon	Elevated liver enzymes and bilirubin.
Very rare	Hepatitis - either hepatocellular or cholestatic, jaundice and hepatic failure (see section 4.4). *
Skin and subcutaneous tissue disorders
Uncommon	Rash, pruritus.
Rare	Hypersensitivity/angioneurotic oedema: angioneurotic oedema of the face, extremities, lips, tongue, glottis, and/or larynx (see section 4.4), urticaria, alopecia, psoriasis.
Very rare	Diaphoresis, pemphigus, toxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme, cutaneous pseudolymphoma. **
Renal and urinary disorders
Common	Renal dysfunction.
Rare	Uraemia, acute renal failure.
Very rare	Oliguria/anuria.
Reproductive system and breast disorders
Uncommon	Impotence.
Rare	Gynaecomastia.
General disorders and administration site conditions
Uncommon	Asthenia, fatigue.
Investigations
Uncommon	Increases in blood urea, increases in serum creatinine, hyperkalaemia.
Rare	Hyponatraemia.

*Very rarely, it has been reported that in some patients the undesirable development of hepatitis has progressed to hepatic failure. Patients receiving lisinopril/hydrochlorothiazide combination who develop jaundice or marked elevation of hepatic enzymes should discontinue lisinopril/hydrochlorothiazide combination and receive appropriate medical follow up.

**A symptom complex has been reported which may include one or more of the following: fever, vasculitis, myalgia, arthralgia/arthritis, a positive antinuclear antibodies (ANA), elevated red blood cell sedimentation rate (ESR), eosinophilia and leucocytosis, rash, photosensitivity or other dermatological manifestations may occur.

Hydrochlorothiazide (freq	uencies unknown):
Infections and infestations	Sialadenitis.
Blood and lymphatic system disorders	Leukopenia, neutropenia/agranulocytosis, thrombocytopenia, aplastic anaemia, haemolytic anaemia, bone marrow depression.
Metabolism and nutrition disorders	Anorexia, hyperglycaemia, glycosuria, hyperuricaemia, electrolyte imbalance (including hyponatraemia and hypokalaemia), increases in cholesterol and triglycerides, gout.
Psychiatric disorders	Restlessness, depression, sleep disturbance.
Nervous system disorders	Loss of appetite, paraesthesia, light-headedness.
Eye disorders	Xanthopsia, transient blurred vision.
Ear and labyrinth disorders	Vertigo.
Cardiac disorders	Postural hypotension.
Vascular disorders	Necrotising angiitis (vasculitis, cutaneous vasculitis).
Respiratory, thoracic and mediastinal disorders	Respiratory distress (including pneumonitis and pulmonary oedema).
Gastrointestinal disorders	Gastric irritation, diarrhoea, constipation, pancreatitis.
Hepatobiliary disorders	Jaundice (intrahepatic cholestatic jaundice).
Skin and subcutaneous tissue disorders	Photosensitivity reactions, rash, cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus, urticaria, anaphylactic reactions, toxic epidermal necrolysis.
Musculo-skeletal, connective tissue and bone disorders	Muscle spasm, muscle weakness.
Renal and urinary disorders	Renal dysfunction, interstitial nephritits.
General disorders	Fever, weakness.

4.9 Overdose

Limited data are available for overdose in humans. Symptoms associated with overdosage of ACE inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety and cough.

The recommended treatment of overdose is intravenous infusion of normal saline solution. If hypotension occurs, the patient should be placed in the supine position. If available, treatment with angiotensin II infusion and/or intravenous catecholamines may also be considered. If ingestion is recent, take measures aimed at eliminating lisinopril (e.g. emesis, gastric lavage, administration of absorbents and sodium sulphate). Lisinopril may be removed from the general circulation by haemodialysis (see section 4.4). Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations should be monitored frequently.

Additional symptoms of hydrochlorothiazide overdose are increased diuresis, depression of consciousness (incl. coma), convulsions, paresis, cardiac arrhythmias and renal failure.

Bradycardia or extensive vagal reactions should be treated by administering atropine.

If digitalis has also been administered hypokalaemia may accentuate cardiac arrhythmias.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: ACE inhibitor (ACE: angiotensin converting enzyme) and thiazide diuretic, ATC-code: C09B A03

This is a fixed dose combination product containing lisinopril, an inhibitor of angiotensin converting enzyme (ACE) and hydrochlorothiazide, a thiazide diuretic. Both components have complementary modes of action and exert an additive antihypertensive effect.

Lisinopril

Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in decreased vasopressor activity and reduced aldosterone secretion.

The latter decrease may result in an increase in serum potassium concentration.

While the mechanism through which lisinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is antihypertensive even in patients with low-renin hypertension. ACE is identical to kininase II, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodilatory peptide, play a role in the therapeutic effects of lisinopril remains to be elucidated.

Hydrochlorothiazide

Hydrochlorothiazide is a diuretic and an antihypertensive agent. It affects the distal renal tubular mechanism of electrolyte reabsorption and increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. The mechanism of the antihypertensive effect of the thiazides is unknown. Thiazides do not usually affect normal blood pressure.

5.2 Pharmacokinetic properties

Concomitant administration of lisinopril and hydrochlorothiazide has little or no effect on the bioavailability of either drug. The combination tablet is bioequivalent to concomitant administration of the separate entities.

Lisinopril

Absorption

Following oral administration of lisinopril, peak serum concentrations occur within about 7 hours, although there was a trend to a small delay in time taken to reach peak serum concentrations in acute myocardial infarction patients. Based on urinary recovery, the mean extent of absorption of lisinopril is approximately 25%, with interpatient variability (6-60%) at all doses tested (580 mg) The absolute bioavailability is reduced approximately 16% in patients with heart failure.

Lisinopril absorption is not affected by the presence of food.

Distribution

Lisinopril does not appear to bind to other serum proteins other than to circulating angiotensin-converting enzyme (ACE).

Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly. Elimination

Lisinopril does not undergo metabolism and absorbed drug is excreted unchanged entirely in the urine.

On multiple dosing lisinopril has an effective half-life of accumulation of 12.6 hours. The clearance of lisinopril in healthy subjects is approximately 50 ml/min. Declining serum concentrations exhibit a prolonged terminal phase, which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to dose.

Hepatic impairment

Impairment of hepatic function in cirrhotic patients resulted in a decrease in lisinopril absorption (about 30% as determined by urinary recovery) but an increase in exposure (approximately 50%) compared to healthy subjects due to decreased clearance.

Renal impairment

Impaired renal function decreases elimination of lisinopril, which is excreted via the kidneys, but this decrease becomes clinically important only when the glomerular filtration rate is below 30 ml/min.

Table 1 Pharmacokinetic parameters of lisinopril to different groups of renal patients after administration of a multiple 5 mg dose
Renal Function Measured by creatinine clearance	n	Cmax (ng/ml)	Tmax (hr)	AUC (0-24 hrs) (ng/hr/ml)	^t1/2 (hr)
>80 ml/min	6	40.3	6	492+/-172	6.0+/-1.1
30 ^_ 80 ml/min	6	36.6	8	555+/-364	11.8+/-1.9
5 ^_ 30 ml/min	6	106.7	8	2228+/-938	19.5+/-5.2

With a creatinine clearance of 30-80ml/min, mean AUC was increased by 13% only, while a 4-5 fold increase in mean AUC was observed with creatinine clearance of 5-30ml/min.

Lisinopril can be removed by dialysis. During 4 hours of haemodialysis, plasma lisinopril concentrations decreased on average by 60%, with a dialysis clearance between 40 and 55 ml/min.

Heart Failure

Patients with heart failure have a greater exposure of lisinopril when compared to healthy subjects (an increase in AUC on average of 125%), but based on the urinary recovery of lisinopril, there is reduced absorption of approximately 16% compared to healthy subjects.

Elderly

Older patients have higher blood levels and higher values for the area under the plasma concentration time curve (increased approximately 60%) than younger patients.

Hydrochlorothiazide

When plasma levels have been followed for at least 24 hours, the plasma halflife has been observed to vary between 5.6 and 14.8 hours.

At least 61% of the dose is eliminated unchanged within 24 hours. After oral hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts 6 to 12 hours.

Hydrochlorothiazide crosses the placental but not the blood-brain barrier.

5.3 Preclinical safety data

Lisinopril and hydrochlorothiazide are both drugs on which extensive clinical experience has been obtained, both separately and in combination. All relevant information for the prescriber is provided elsewhere in the Summary of Product Characteristics.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Each tablet contains:

Silica, colloidal anhydrous Magnesium stearate Sodium laurilsulfate Cellulose, microcrystalline (E460)

Maize starch, pregelatinized Calcium hydrogen phosphate dihydrate Mannitol (E421)

Croscarmellose sodium Povidone (K29/32)

Iron oxide red (E172) (only the 10 mg/12.5 mg tablet) Iron oxide yellow (E172) (only the 10 mg/12.5 mg tablet)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

Blisters packs:

3 years

Bottle packs:

As packaged for sale: 3 years After first opening: 30 days

6.4 Special precautions for storage

6.5 Nature and contents of container

Alu/Alu (cold form) blister: 10, 14, 28, 30, 50, 56, 84, 90 & 100 Alu/Alu (cold form) perforated unit dose blisters: 100 x 1 tablet PVC/PVdC/Alu blister: 10, 14, 28, 30, 50, 56, 84, 90 & 100 PVC/PVdC/Alu perforated unit dose blisters: 100 x 1 tablet HDPE bottle: 500

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements for disposal.

7 MARKETING AUTHORISATION HOLDER

McDermott Laboratoires Limited 35-36 Baldoyle Industrial Estate Grange Road Dublin 13 Ireland

8 MARKETING AUTHORISATION NUMBER(S)

PL 11896/0026

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 04/11/2011

10 DATE OF REVISION OF THE TEXT

27/11/2014